All News
Is MSOT the New Ultrasound?
Dr. Aurelie Najm reports on oral abstract 0750 presented at #ACR23
https://t.co/okbGHTR0i3 https://t.co/9zkHPiFl74
Dr. John Cush RheumNow ( View Tweet)
Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis
Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23
https://t.co/avnarOGZui https://t.co/4CeAumv31b
Dr. John Cush RheumNow ( View Tweet)
Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increases IL-1B, IL-6, GM-CSF, CCL20 (recruits T cells), CCL2 (recruits monocytes), VEGF (neoangiogenic). Abstr#2599 #ACR23 @RheumNow https://t.co/p4GumZStAZ https://t.co/zZv0TF4fmn
Richard Conway ( View Tweet)
Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU
Dr. Antoni Chan ( View Tweet)
#ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg
Md Yuzaiful Md Yusof ( View Tweet)
A randomised clinical trial show improvements in clinical outcomes CDAI, VAS for both the ITIS diet and the Med diet. Baseline differences in the microbiome between responders and non-responders were seen. Sala Climent M, Abst#2124 #ACR23 @RheumNow https://t.co/tiyNcV7cmD https://t.co/EEP4zrwjXs
Dr. Antoni Chan ( View Tweet)
Abstract 2583 at #ACR23
👉Possible predictive model of at risk of RA patients with ACPA positivity based on baseline levels of peripheral blood lymphocyte sub-populations:
⭐️High % of B cell and low % of NK cells increase the probability of developing arthritis in ACPA + pts… https://t.co/3KEOI4eul0 https://t.co/irX6InWMbl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
Robert B Chao, MD ( View Tweet)
Saliclick: minor salivary gland biopsy was a safe and rapid procedure for the diagnosis in Sjögren’s Syndrome without observed numbness occurring, focal lymphocytic sialadenitis in 20%, with a focus score >1 for 62%. Hugle T, Abst#2190 #ACR23 @RheumNow https://t.co/VYKdQw2YlC https://t.co/dWLWj2AdkI
Dr. Antoni Chan ( View Tweet)
Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study
Decline in FVC over 52 weeks decreased by 57% on nintedanib
But am I also just seeing a study FVC decline even with nintedanib?
@RheumNow #ACR23 Abs#2594 https://t.co/3h4mhm0ceU
Robert B Chao, MD ( View Tweet)
A model for prediction of progression to RA
Factors asso w/ progression
-ACPAs
-High % B cells
-Low % NK cells
Only in ACPA+ individuals
Low ACPA titers, High % NK cells and Low B cells = 76% non progressors
@RheumNow #ACR23 ABST2583 https://t.co/vNIwyrOJtJ
Aurelie Najm ( View Tweet)
AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrease in total urate crystal volume of the feet and ankles after AR882 75 mg once daily for 6 months. Keenan R, Abst#L15 #ACR23 @RheumNow https://t.co/gMCcSI1v9W https://t.co/lk3XQCaw0A
Dr. Antoni Chan ( View Tweet)
⭐️Further Assessment of a patient with rash c/w leukocytoclastic vasculitis:
👉History:
⏺️Timing, onset, progression?
⏺️Recent infectious for infectious symptoms?
⏺️Recent/new meds?
⏺️Hx of cancer?
👉Laboratory assessment for ALL:
⏺️CBC w/ diff
⏺️CMP (w/ interest in Cr,… https://t.co/tVqz6XDXt2 https://t.co/LqZpx5j0Bp
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
1st Large real world observational head to head study on tx of Systemic sclerosis - ILD
No difference in treatment effectiveness of FVC change between tocilizumab, rituximab, mycophenolate and cyclophosphamide!
@RheumNow #ACR23 Abs#2596
#ACRBest https://t.co/GaSnZSCcnZ
Robert B Chao, MD ( View Tweet)
Fecal transplant for treatment of GI complications of systemic sclerosis?
No change in those who received transplant...
Overall procedure safe
@RheumNow #ACR23 Abs#2597 https://t.co/TEdeGHuzpi
Robert B Chao, MD ( View Tweet)
JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA
Dr. Antoni Chan ( View Tweet)
Fecal microbiota - can it predict development of RA?
Sadly, no. Despite promising mouse work. Despite relative control of exposure & genetic enrichment incl SE. Not even Prevotella. Maybe if you compare the most extreme cases
but it’s not all the gut.
#ACR23 ABST2584 @RheumNow https://t.co/VgDZaH9kvo
David Liew drdavidliew ( View Tweet)
Pre-clinical RA trials roundup, but also:
Great use (and acknowledgment) of RheumNow slide in the abstract background. Glad to see it being helpful there!
#ACR23 ABST2585 @RheumNow https://t.co/sK6bDJrYjV
David Liew drdavidliew ( View Tweet)
Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
Dr. Antoni Chan ( View Tweet)